Drug
Rap 219
Rap 219: highest development phase Phase 3, developed by Rapport Therapeutics Inc.. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Rapport Therapeutics Inc.
Trials
| Drug | Phase | Indication |
|---|---|---|
| RAP-219 NCT07594119 | Phase 3 | Focal Seizure |
| RAP-219 NCT07563881 | Phase 3 | Focal Seizure |
Latest
No recent events.
Follow Rap 219 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.